These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33348023)

  • 1. Anlotinib enhances the antitumor activity of radiofrequency ablation on lung squamous cell carcinoma.
    Zhou W; Gao Y; Tong Y; Wu Q; Zhou Y; Li Y
    Pharmacol Res; 2021 Feb; 164():105392. PubMed ID: 33348023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma.
    Tang H; You T; Ge H; Gao J; Wang Y; Bai C; Sun Z; Han Q; Zhao RC
    Int Immunopharmacol; 2024 May; 133():112053. PubMed ID: 38615380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
    Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
    Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppressed mitochondrial respiration via NOX5-mediated redox imbalance contributes to the antitumor activity of anlotinib in oral squamous cell carcinoma.
    Huang Z; Su Q; Li W; Ren H; Huang H; Wang A
    J Genet Genomics; 2021 Jul; 48(7):582-594. PubMed ID: 34373220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effects of anlotinib in thyroid cancer.
    Ruan X; Shi X; Dong Q; Yu Y; Hou X; Song X; Wei X; Chen L; Gao M
    Endocr Relat Cancer; 2019 Jan; 26(1):153-164. PubMed ID: 30139768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NEAT 1 knockdown enhances the sensitivity of human non-small-cell lung cancer cells to anlotinib.
    Gu G; Hu C; Hui K; Chen T; Zhang H; Jiang X
    Aging (Albany NY); 2021 May; 13(10):13941-13953. PubMed ID: 33982669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. METTL3 inhibitor STM2457 impairs tumor progression and enhances sensitivity to anlotinib in OSCC.
    Liu L; Zhao T; Zheng S; Tang D; Han H; Yang C; Zheng X; Wang J; Ma J; Wei W; Wang Z; He S; He Q
    Oral Dis; 2024 Oct; 30(7):4243-4254. PubMed ID: 38376115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
    Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
    Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells.
    Liang L; Hui K; Hu C; Wen Y; Yang S; Zhu P; Wang L; Xia Y; Qiao Y; Sun W; Fei J; Chen T; Zhao F; Yang B; Jiang X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):71. PubMed ID: 30755242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-6077 enhances the sensitivity of patients-derived lung adenocarcinoma cells to anlotinib by repressing the activation of glucose transporter 1 pathway.
    Ma DB; Qin MM; Shi L; Ding XM
    Cell Signal; 2019 Dec; 64():109391. PubMed ID: 31421224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anlotinib Suppresses Oral Squamous Cell Carcinoma Growth and Metastasis by Targeting the RAS Protein to Inhibit the PI3K/Akt Signalling Pathway.
    Lu Y; Lin J; Duan M; Rui Y; Zheng H; Zhu L; Zhu X; Wei J
    Anal Cell Pathol (Amst); 2021; 2021():5228713. PubMed ID: 34926131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel multi-target tyrosine kinase inhibitor anlotinib combined with irinotecan has in-vitro anti-tumor activity against human small-cell lung cancer.
    Li H; Liu Y; Liu X; Zhao D; Liu J; Cheng Y
    Anticancer Drugs; 2020 Nov; 31(10):1057-1064. PubMed ID: 32694423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer.
    Zhang C; Cao H; Cui Y; Jin S; Gao W; Huang C; Guo R
    Thorac Cancer; 2021 Oct; 12(19):2574-2584. PubMed ID: 34510760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
    Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
    Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
    Xie C; Wan X; Quan H; Zheng M; Fu L; Li Y; Lou L
    Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anlotinib inhibits the progress of colorectal cancer cells by antagonizing VEGFR/JAK2/STAT3 axis.
    Jia ZX; Zhang Z; Li Z; Li A; Xie YN; Wu HJ; Yang ZB; Zhang HM; Zhang XM
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2331-2343. PubMed ID: 33755971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through Merlin.
    Torres-Ayuso P; An E; Nyswaner KM; Bensen RC; Ritt DA; Specht SI; Das S; Andresson T; Cachau RE; Liang RJ; Ries AL; Robinson CM; Difilippantonio S; Gouker B; Bassel L; Karim BO; Miller CJ; Turk BE; Morrison DK; Brognard J
    Cancer Discov; 2021 Jun; 11(6):1411-1423. PubMed ID: 33495197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of anlotinib in malignant melanoma: modulation of angiogenesis and vasculogenic mimicry.
    Yang Q; Li Q; Fan H
    Arch Dermatol Res; 2024 Jul; 316(7):447. PubMed ID: 38958761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anlotinib: First Global Approval.
    Syed YY
    Drugs; 2018 Jul; 78(10):1057-1062. PubMed ID: 29943374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling.
    Qin T; Liu Z; Wang J; Xia J; Liu S; Jia Y; Liu H; Li K
    Cancer Biol Med; 2020 Aug; 17(3):753-767. PubMed ID: 32944404
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.